Rhythm’s Imcivree (setmelanotide) Receives EC’s Approval for the Treatment of Bardet-Biedl Syndrome
- The EC has approved Imcivree for the treatment of obesity and control of hunger associated with genetically confirmed BBS in adult & pediatric patients (≥6yrs.) with impairments in the MC4R pathway due to genetic diseases
- The expansion of Imcivree has led to the eligibility of Rhythm to receive an additional investment of $37.5M under the Revenue Interest Agreement with HealthCare Royalty & remains eligible to receive an additional investment amount of $25M payable upon achievement of agreed sales milestones in 2023
- Additionally, Imcivree has received a Priority Review from Health Canada for the treatment of obesity & control of hunger in BBS, biallelic POMC, PCSK1, or LEPR deficiency
Ref: Globenewswire | Image: Rhythm
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.